Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2004 Jul;48(7):2719-23.
doi: 10.1128/AAC.48.7.2719-2723.2004.

In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci

Affiliations
Comparative Study

In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci

Vanthida Huang et al. Antimicrob Agents Chemother. 2004 Jul.

Abstract

We examined the activity of CB-181963, a novel cephalosporin, against methicillin-resistant Staphylococcus aureus (MRSA) (n = 200), methicillin-susceptible S. aureus (MSSA) (n = 50), glycopeptide-intermediate Staphylococcus species (GISS) (n = 47), and VRSA (n = 2) isolates. CB-181963 exhibited MIC profiles similar to those of linezolid against MRSA and GISS; however, activity against MSSA was similar to that of vancomycin. Time-kill study results of investigations of activity against MRSA, MSSA, and GISS at 24 h were as follows: CB-181963 activity = vancomycin activity > linezolid activity (P < 0.001); CB-181963 = quinupristin-dalfopristin = vancomycin > linezolid (P < 0.05); CB-181963 > linezolid (P = 0.003); and CB-181963 = quinupristin-dalfopristin = vancomycin. CB-181963 may provide an alternative treatment for multidrug-resistant staphylococci.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
CB-181963 chemical structure.
FIG. 2.
FIG. 2.
Time-kill experiments at four times the MIC for a combination of four selected clinical MRSA strains (A), four times the MIC for four selected clinical MSSA strains (B), two times the MIC for a combination of four selected clinical GISS strains (including three S. aureus and one S. epidermidis strains; the drug MIC for all strains was 8 μg/ml) (C), and two times the MIC for clinical strains of VRSA-MI and VRSA-PA (D and E). Results represent means ± standard deviations. GC, growth control; C, CB-181963; L, linezolid; Q-D, quinupristin-dalfopristin; V, vancomycin.
FIG. 2.
FIG. 2.
Time-kill experiments at four times the MIC for a combination of four selected clinical MRSA strains (A), four times the MIC for four selected clinical MSSA strains (B), two times the MIC for a combination of four selected clinical GISS strains (including three S. aureus and one S. epidermidis strains; the drug MIC for all strains was 8 μg/ml) (C), and two times the MIC for clinical strains of VRSA-MI and VRSA-PA (D and E). Results represent means ± standard deviations. GC, growth control; C, CB-181963; L, linezolid; Q-D, quinupristin-dalfopristin; V, vancomycin.

References

    1. Ariza, J., M. Pujol, J. Cabo, C. Pena, N. Fernandez, T. Linares, J. Ayats, and F. Gudiol. 1999. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 353:1587-1588. - PubMed
    1. Bert, F., J. Clarissou, F. Durand, D. Delefosse, C. Chauvet, P. Lefebvre, N. Lambert, and C. Branger. 2003. Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients. J. Clin. Microbiol. 41:5147-5152. - PMC - PubMed
    1. Bierbaum, G., K. Fuchs, W. Lenz, and H.-G. Sahl. 1999. Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. Eur. J. Clin. Microbiol. Infect. Dis. 18:691-696. - PubMed
    1. Centers for Disease Control and Prevention. 1996. Reduced susceptibility of Staphylococcus aureus to vancomycin—Japan 1996. Morb. Mortal. Wkly. Rep. 46:624-626. - PubMed
    1. Centers for Disease Control and Prevention. 1997. Staphylococcus aureus with reduced susceptibility to vancomycin—United States, 1997. Morb. Mortal. Wkly. Rep. 46:765-766. - PubMed

Publication types

MeSH terms